Search

Your search keyword '"Grebely, Jason"' showing total 1,369 results
Start Over Author "Grebely, Jason"
1,369 results on '"Grebely, Jason"'

152. A systematic scoping review of the characteristics of contingency management interventions evaluated for the treatment of substance use disorders

Author

McKetin, Rebecca, Degenhardt, Louisa, Farrell, Michael, Sutherland, Rachel, Clay, Simon, Colledge, Samantha, Grebely, Jason, Marshall, Alison, Arunogiri, Shalini, Ginley, Meredith, Nagle, Jack, Christmass, Michael, MacCartney, Paul, Membrey, Dean, and Wilkinson, Zachary

Subjects
contingency management, Mental and Social Health, substance use disorder, Medicine and Health Sciences, Psychiatry and Psychology, Substance Abuse and Addiction, Public Health, Health Services Research, scoping review
Abstract

This is a systematic scoping review aiming to describe the characteristics of contingency management interventions that have been evaluated for the treatment of substance use disorders (e.g., implementation setting, reinforcement schedules, goals). It is anticipated that this review will be a precursor to an evaluation of the effectiveness of different contingency management protocols to treat substance use disorders.

Published
2022
Full Text
View/download PDF

154. Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection

Author

Dalgard, Olav, primary, Litwin, Alain H., additional, Shibolet, Oren, additional, Grebely, Jason, additional, Nahass, Ronald, additional, Altice, Frederick L., additional, Conway, Brian, additional, Gane, Edward J., additional, Luetkemeyer, Anne F., additional, Peng, Cheng-Yuan, additional, Iser, David, additional, Gendrano, Isaias Noel, additional, Kelly, Michelle M., additional, Haber, Barbara A., additional, Platt, Heather, additional, and Puenpatom, Amy, additional

Published
2022
Full Text
View/download PDF

155. A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study

Author

Conway, Anna, primary, Valerio, Heather, additional, Alavi, Maryam, additional, Silk, David, additional, Treloar, Carla, additional, Hajarizadeh, Behzad, additional, Marshall, Alison D., additional, Martinello, Marianne, additional, Milat, Andrew, additional, Dunlop, Adrian, additional, Murray, Carolyn, additional, Prain, Bianca, additional, Henderson, Charles, additional, Amin, Janaki, additional, Read, Phillip, additional, Marks, Pip, additional, Degenhardt, Louisa, additional, Hayllar, Jeremy, additional, Reid, David, additional, Gorton, Carla, additional, Lam, Thao, additional, Christmass, Michael, additional, Wade, Alexandra, additional, Montebello, Mark, additional, Dore, Gregory J., additional, and Grebely, Jason, additional

Published
2022
Full Text
View/download PDF

158. Hepatitis C virus reinfection following direct acting antiviral treatment in the prison setting: the SToP-C study

Author

Carson, Joanne, primary, Dore, Gregory, additional, Lloyd, Andrew, additional, Grebely, Jason, additional, Byrne, Marianne, additional, Cunningham, Evan B, additional, Amin, Janaki, additional, Vickerman, Peter, additional, Martin, Natasha, additional, Treloar, Carla, additional, Matthews, Gail, additional, and Hajarizadeh, Behzad, additional

Published
2022
Full Text
View/download PDF

159. Willingness of people who inject drugs to participate in a randomised controlled trial involving financial incentives to initiate hepatitis C treatment

Author

Marshall, Alison D., primary, Conway, Anna, additional, Cunningham, Evan B., additional, Valerio, Heather, additional, Silk, David, additional, Alavi, Maryam, additional, Wade, Alexandra, additional, Lam, Thao, additional, Zohrab, Krista, additional, Dunlop, Adrian, additional, Connelly, Chris, additional, Christmass, Michael, additional, Cock, Victoria, additional, Burns, Carina, additional, Henderson, Charles, additional, Wiseman, Virginia, additional, Dore, Gregory J., additional, and Grebely, Jason, additional

Published
2022
Full Text
View/download PDF

168. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

Author

Howe, Anita Y. M., Rodrigo, Chaturaka, Cunningham, Evan B., Douglas, Mark W., Dietz, Julia, Grebely, Jason, Popping, Stephanie, Sfalcin, Javier Alejandro, Parczewski, Milosz, Sarrazin, Christoph, de Salazar, Adolfo, Fuentes, Ana, Sayan, Murat, Quer, Josep, Kjellin, Midori, Kileng, Hege, Mor, Orna, Lennerstrand, Johan, Fourati, Slim, Di Maio, Velia Chiara, Chulanov, Vladimir, Pawlotsky, Jean-Michel, Harrigan, P. Richard, Ceccherini-Silberstein, Francesca, Garcia, Federico, Howe, Anita Y. M., Rodrigo, Chaturaka, Cunningham, Evan B., Douglas, Mark W., Dietz, Julia, Grebely, Jason, Popping, Stephanie, Sfalcin, Javier Alejandro, Parczewski, Milosz, Sarrazin, Christoph, de Salazar, Adolfo, Fuentes, Ana, Sayan, Murat, Quer, Josep, Kjellin, Midori, Kileng, Hege, Mor, Orna, Lennerstrand, Johan, Fourati, Slim, Di Maio, Velia Chiara, Chulanov, Vladimir, Pawlotsky, Jean-Michel, Harrigan, P. Richard, Ceccherini-Silberstein, Francesca, and Garcia, Federico

Abstract

Background & Aims: Direct-acting antiviral (DAA) regimens provide a cure in >95% of patients with chronic HCV infection. However, in some patients in whom therapy fails, resistance-associated substitutions (RASs) can develop, limiting retreatment options and risking onward resistant virus transmission. In this study, we evaluated RAS prevalence and distribution, including novel NS5A RASs and clinical factors associated with RAS selection, among patients who experienced DAA treatment failure. Methods: SHARED is an international consortium of clinicians and scientists studying HCV drug resistance. HCV sequence linked metadata from 3,355 patients were collected from 22 countries. NS3, NS5A, and NS5B RASs in virologic failures, including novel NS5A substitutions, were examined. Associations of clinical and demographic characteristics with RAS selection were investigated. Results: The frequency of RASs increased from its natural prevalence following DAA exposure: 37% to 60% in NS3, 29% to 80% in NS5A, 15% to 22% in NS5B for sofosbuvir, and 24% to 37% in NS5B for dasabuvir. Among 730 virologic failures, most were treated with first-generation DAAs, 94% had drug resistance in >-1 DAA class: 31% single-class resistance, 42% dual-class resistance (predominantly against protease and NS5A inhibitors), and 21% triple-class resistance. Distinct patterns containing >-2 highly resistant RASs were common. New potential NS5A RASs and adaptive changes were identified in genotypes 1a, 3, and 4. Following DAA failure, RAS selection was more frequent in older people with cirrhosis and those infected with genotypes 1b and 4. Conclusions: Drug resistance in HCV is frequent after DAA treatment failure. Previously unrecognized substitutions continue to emerge and remain uncharacterized.Lay summary: Although direct-acting antiviral medications effectively cure hepatitis C in most patients, sometimes treatment selects for resistant viruses, causing antiviral drugs to be either in

Published
2022
Full Text
View/download PDF

169. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

Author

Howe, Anita Y.M., Rodrigo, Chaturaka, Cunningham, Evan B., Douglas, Mark W., Dietz, Julia, Grebely, Jason, Popping, Stephanie, Sfalcin, Javier Alejandro, Parczewski, Milosz, Sarrazin, Christoph, de Salazar, Adolfo, Fuentes, Ana, Sayan, Murat, Quer, Josep, Kjellin, Midori, Kileng, Hege, Mor, Orna, Lennerstrand, Johan, Fourati, Slim, Di Maio, Velia Chiara, Chulanov, Vladimir, Pawlotsky, Jean Michel, Harrigan, P. Richard, Ceccherini-Silberstein, Francesca, Garcia, Federico, Howe, Anita Y.M., Rodrigo, Chaturaka, Cunningham, Evan B., Douglas, Mark W., Dietz, Julia, Grebely, Jason, Popping, Stephanie, Sfalcin, Javier Alejandro, Parczewski, Milosz, Sarrazin, Christoph, de Salazar, Adolfo, Fuentes, Ana, Sayan, Murat, Quer, Josep, Kjellin, Midori, Kileng, Hege, Mor, Orna, Lennerstrand, Johan, Fourati, Slim, Di Maio, Velia Chiara, Chulanov, Vladimir, Pawlotsky, Jean Michel, Harrigan, P. Richard, Ceccherini-Silberstein, Francesca, and Garcia, Federico

Abstract

Background & Aims: Direct-acting antiviral (DAA) regimens provide a cure in >95% of patients with chronic HCV infection. However, in some patients in whom therapy fails, resistance-associated substitutions (RASs) can develop, limiting retreatment options and risking onward resistant virus transmission. In this study, we evaluated RAS prevalence and distribution, including novel NS5A RASs and clinical factors associated with RAS selection, among patients who experienced DAA treatment failure. Methods: SHARED is an international consortium of clinicians and scientists studying HCV drug resistance. HCV sequence linked metadata from 3,355 patients were collected from 22 countries. NS3, NS5A, and NS5B RASs in virologic failures, including novel NS5A substitutions, were examined. Associations of clinical and demographic characteristics with RAS selection were investigated. Results: The frequency of RASs increased from its natural prevalence following DAA exposure: 37% to 60% in NS3, 29% to 80% in NS5A, 15% to 22% in NS5B for sofosbuvir, and 24% to 37% in NS5B for dasabuvir. Among 730 virologic failures, most were treated with first-generation DAAs, 94% had drug resistance in ≥1 DAA class: 31% single-class resistance, 42% dual-class resistance (predominantly against protease and NS5A inhibitors), and 21% triple-class resistance. Distinct patterns containing ≥2 highly resistant RASs were common. New potential NS5A RASs and adaptive changes were identified in genotypes 1a, 3, and 4. Following DAA failure, RAS selection was more frequent in older people with cirrhosis and those infected with genotypes 1b and 4. Conclusions: Drug resistance in HCV is frequent after DAA treatment failure. Previously unrecognized substitutions continue to emerge and remain uncharacterized. Lay summary: Although direct-acting antiviral medications effectively cure hepatitis C in most patients, sometimes treatment selects for resistant viruses, causing antiviral drugs to be either ineffe

Published
2022

173. Prison‐based interventions are key to achieving HCV elimination among people who inject drugs in New South Wales, Australia: A modelling study.

Author

Stone, Jack, Lim, Aaron G., Dore, Gregory J., Borquez, Annick, Geddes, Louise, Gray, Richard, Grebely, Jason, Hajarizadeh, Bezhad, Iversen, Jenny, Maher, Lisa, Valerio, Heather, Martin, Natasha K., Hickman, Matthew, Lloyd, Andrew R., and Vickerman, Peter

Subjects
HEPATITIS C virus, COMMUNITIES
Abstract

Background & Aims: People who inject drugs (PWID) experience high incarceration rates which are associated with increased hepatitis C virus (HCV) transmission risk. We assess the importance of prison‐based interventions for achieving HCV elimination among PWID in New South Wales (NSW), Australia. Methods: A model of incarceration and HCV transmission among PWID was calibrated in a Bayesian framework to epidemiological and incarceration data from NSW, incorporating elevated HCV acquisition risk among recently released PWID. We projected the contribution of differences in transmission risk during/following incarceration to HCV transmission over 2020–2029. We estimated the past and potential future impact of prison‐based opioid agonist therapy (OAT; ~33% coverage) and HCV treatment (1500 treatments in 2019 with 32.9%–83.3% among PWID) on HCV transmission. We estimated the time until HCV incidence reduces by 80% (WHO elimination target) compared to 2016 levels with or without prison‐based interventions. Results: Over 2020–2029, incarceration will contribute 23.0% (17.9–30.5) of new HCV infections. If prison‐based interventions had not been implemented since 2010, HCV incidence in 2020 would have been 29.7% (95% credibility interval: 22.4–36.1) higher. If current prison and community HCV treatment rates continue, there is an 98.8% probability that elimination targets will be achieved by 2030, with this decreasing to 10.1% without current prison‐based interventions. Conclusions: Existing prison‐based interventions in NSW are critical components of strategies to reduce HCV incidence among PWID. Prison‐based interventions are likely to be pivotal for achieving HCV elimination targets among PWID by 2030. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

178. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

Author

Howe, Anita Y.M., primary, Rodrigo, Chaturaka, additional, Cunningham, Evan B., additional, Douglas, Mark W., additional, Dietz, Julia, additional, Grebely, Jason, additional, Popping, Stephanie, additional, Sfalcin, Javier Alejandro, additional, Parczewski, Milosz, additional, Sarrazin, Christoph, additional, de Salazar, Adolfo, additional, Fuentes, Ana, additional, Sayan, Murat, additional, Quer, Josep, additional, Kjellin, Midori, additional, Kileng, Hege, additional, Mor, Orna, additional, Lennerstrand, Johan, additional, Fourati, Slim, additional, Di Maio, Velia Chiara, additional, Chulanov, Vladimir, additional, Pawlotsky, Jean-Michel, additional, Harrigan, P. Richard, additional, Ceccherini-Silberstein, Francesca, additional, Garcia, Federico, additional, Martinello, Marianne, additional, Matthews, Gail, additional, Fernando, Fay Fabián, additional, Esteban, Juan I., additional, Müllhaupt, Beat, additional, Wiesch, Julian Schulze zur, additional, Buggisch, Peter, additional, Neumann-Haefelin, Christoph, additional, Berg, Thomas, additional, Berg, Christoph P., additional, Schattenberg, Jörn M., additional, Moreno, Christophe, additional, Stauber, Rudolf, additional, Lloyd, Andrew, additional, Dore, Gregory, additional, Applegate, Tanya, additional, Ignacio, Juan, additional, Garcia-Cehic, Damir, additional, Gregori, Josep, additional, Rodriguez-Frias, Francisco, additional, Rando, Ariadna, additional, Gozlan, Yael, additional, Angelico, Mario, additional, Andreoni, Massimo, additional, Babudieri, Sergio, additional, Bertoli, Ada, additional, Cento, Valeria, additional, Coppola, Nicola, additional, Craxì, Antonio, additional, Paolucci, Stefania, additional, Parruti, Giustino, additional, Pasquazzi, Caterina, additional, Perno, Carlo Federico, additional, Teti, Elisabetta, additional, Vironet, C., additional, Lannergård, Anders, additional, Duberg, Ann-Sofi, additional, Aleman, Soo, additional, Gutteberg, Tore, additional, Soulier, Alexandre, additional, Gourgeon, Aurélie, additional, Chevaliez, Stephane, additional, Pol, Stanislas, additional, Carrat, Fabrice, additional, Salmon, Dominique, additional, Kaiser, Rolf, additional, Knopes, Elena, additional, Gomes, Perpetua, additional, de Kneght, Rob, additional, Rijnders, Bart, additional, Poljak, Mario, additional, Lunar, Maja, additional, Usubillaga, Rafael, additional, Seguin_Devaux, Carole, additional, Tay, Enoch, additional, Wilson, Caroline, additional, Wang, Dao Sen, additional, George, Jacob, additional, Kok, Jen, additional, Pérez, Ana Belén, additional, Chueca, Natalia, additional, García-Deltoro, Miguel, additional, Martínez-Sapiña, Ana María, additional, Lara-Pérez, María Magdalena, additional, García-Bujalance, Silvia, additional, Aldámiz-Echevarría, Teresa, additional, Vera-Méndez, Francisco Jesús, additional, Pineda, Juan Antonio, additional, Casado, Marta, additional, Pascasio, Juan Manuel, additional, Salmerón, Javier, additional, Alados-Arboledas, Juan Carlos, additional, Poyato, Antonio, additional, Téllez, Francisco, additional, Rivero-Juárez, Antonio, additional, Merino, Dolores, additional, Vivancos-Gallego, María Jesús, additional, Rosales-Zábal, José Miguel, additional, Ocete, María Dolores, additional, Simón, Miguel Ángel, additional, Rincón, Pilar, additional, Reus, Sergi, additional, De la Iglesia, Alberto, additional, García-Arata, Isabel, additional, Jiménez, Miguel, additional, Jiménez, Fernando, additional, Hernández-Quero, José, additional, Galera, Carlos, additional, Balghata, Mohamed Omar, additional, Primo, Joaquín, additional, Masiá, Mar, additional, Espinosa, Nuria, additional, Delgado, Marcial, additional, von-Wichmann, Miguel Ángel, additional, Collado, Antonio, additional, Santos, Jesús, additional, Mínguez, Carlos, additional, Díaz-Flores, Felícitas, additional, Fernández, Elisa, additional, Bernal, Enrique, additional, De Juan, José, additional, Antón, José Joaquín, additional, Vélez, Mónica, additional, Aguilera, Antonio, additional, Navarro, Daniel, additional, Arenas, Juan Ignacio, additional, Fernández, Clotilde, additional, Espinosa, María Dolores, additional, Ríos, María José, additional, Alonso, Roberto, additional, Hidalgo, Carmen, additional, Hernández, Rosario, additional, Téllez, María Jesús, additional, Rodríguez, Francisco Javier, additional, Antequera, Pedro, additional, Delgado, Cristina, additional, Martín, Patricia, additional, Crespo, Javier, additional, Becerril, Berta, additional, Pérez, Oscar, additional, García-Herola, Antonio, additional, Montero, José, additional, Freyre, Carolina, additional, Grau, Concepción, additional, Cabezas, Joaquin, additional, Jimenez, Miguel, additional, Rodriguez, Manuel Alberto Macias, additional, Quilez, Cristina, additional, Pardo, Maria Rodriguez, additional, Muñoz-Medina, Leopoldo, additional, and Figueruela, Blanca, additional

Published
2022
Full Text
View/download PDF

183. Diagnostic Accuracy of Assays Using Point-of-Care Testing or Dried Blood Spot Samples for the Determination of Hepatitis C Virus RNA: A Systematic Review

Author

Catlett, Beth, primary, Hajarizadeh, Behzad, additional, Cunningham, Evan, additional, Wolfson-Stofko, Brett, additional, Wheeler, Alice, additional, Khandaker-Hussain, Benazir, additional, Feld, Jordan J, additional, Martró, Elisa, additional, Chevaliez, Stéphane, additional, Pawlotsky, Jean Michel, additional, Bharat, Chrianna, additional, Cunningham, Philip H, additional, Dore, Gregory J, additional, Applegate, Tanya, additional, and Grebely, Jason, additional

Published
2022
Full Text
View/download PDF

184. Optimizing Point-of-Care Testing Strategies for Diagnosis and Treatment of Hepatitis C Virus Infection in Australia: A Model-Based Cost-Effectiveness Analysis

Author

Shih, Sophy TF, primary, Cheng, Qinglu, additional, Carson, Joanne, additional, Valerio, Heather, additional, Sheehan, Yumi, additional, Gray, Richard T., additional, Cunningham, Evan B., additional, Kwon, Jisoo, additional, Lloyd, Andrew R., additional, Dore, Gregory J., additional, Wiseman, Virginia, additional, and Grebely, Jason, additional

Published
2022
Full Text
View/download PDF

185. Hepatitis C Virus Transmission Dynamics in a Global Cohort of Men Who Have Sex with Men with Recently Acquired Infection

Author

Koopsen, Jelle, primary, Matthews, Gail, additional, Rockstroh, Jürgen K., additional, Applegate, Tanya L., additional, Bhagani, Sanjay R., additional, Grebely, Jason, additional, Rauch, Andri, additional, Sacks-Davis, Rachel, additional, Ingiliz, Patrick, additional, Boesecke, Christoph, additional, Rebers, Sjoerd, additional, Feld, Jordan, additional, Bruneau, Julie, additional, Martinello, Marianne, additional, Hellard, Margaret Elena, additional, Dore, Gregory J., additional, Schinkel, Janke, additional, van der Valk, Marc, additional, and Study Group, REACT, additional

Published
2022
Full Text
View/download PDF

188. Evaluation of Simplified HCV Diagnostics in HIV/HCV Co-Infected Patients in Myanmar.

Author

Nyein, Phyo Pyae, Tillakeratne, Shane, Phyu, Sabai, Yee, Myint Myint, Lwin, Mya Mya, Htike, Kyaw Linn, Aung, May Thu, Grebely, Jason, Applegate, Tanya, Hanson, Josh, Matthews, Gail, and Lin, Kyaw Swar

Subjects
HEPATITIS C virus, MEDICAL protocols, HIV, ANTIRETROVIRAL agents, ODDS ratio
Abstract

To evaluate a decentralised testing model and simplified treatment protocol of hepatitis C virus (HCV) infection to facilitate treatment scale-up in Myanmar, this prospective, observational study recruited HIV–HCV co-infected outpatients receiving sofosbuvir/daclatasvir in Yangon, Myanmar. The study examined the outcomes and factors associated with a sustained virological response (SVR). A decentralised "hub-and-spoke" testing model was evaluated where fingerstick capillary specimens were transported by taxi and processed centrally. The performance of the Xpert HCV VL Fingerstick Assay in detecting HCV RNA was compared to the local standard of care (plasma HCV RNA collected by venepuncture). Between January 2019 and February 2020, 162 HCV RNA-positive individuals were identified; 154/162 (95%) initiated treatment, and 128/154 (84%) returned for their SVR12 visit. A SVR was achieved in 119/154 (77%) participants in the intent-to-treat population and 119/128 (93%) participants in the modified-intent-to-treat population. Individuals receiving an antiretroviral therapy were more likely to achieve a SVR (with an odds ratio (OR) of 7.16, 95% CI 1.03–49.50), while those with cirrhosis were less likely (OR: 0.26, 95% CI 0.07–0.88). The sensitivity of the Xpert HCV VL Fingerstick Assay was 99.4% (95% CI 96.7–100.0), and the specificity was 99.2% (95% CI 95.9–99.9). A simplified treatment protocol using a hub-and-spoke testing model of fingerstick capillary specimens can achieve an SVR rate in LMIC comparable to well-resourced high-income settings. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

189. Hepatitis C virus‐specific immune responses following direct‐acting antivirals administered during recent hepatitis C virus infection.

Author

Casey, Julia L., Dore, Gregory J., Grebely, Jason, Matthews, Gail V., Cherepanov, Vera, Martinello, Marianne, Marks, Philippa, Janssen, Harry L. A., Hansen, Bettina E., Kaul, Rupert, MacParland, Sonya A., Gehring, Adam J., and Feld, Jordan J.

Subjects
HEPATITIS C, ANTIVIRAL agents, HEPATITIS C virus, IMMUNE response, PLANT viruses, MATERNALLY acquired immunity, HEPATITIS
Abstract

Individuals who spontaneously clear hepatitis C virus (HCV) infection have demonstrated evidence of partial protective immunity, whereas treatment‐induced clearance provides little or no protection against reinfection. We aimed to investigate whether treatment of acute HCV infection with direct‐acting antivirals (DAA) prevents establishment of, or reverses, T‐cell exhaustion, leading to a virus‐specific T‐cell immune profile more similar to that seen in spontaneous clearance. The magnitude and breadth of HCV‐specific T‐cell responses before and after DAA or interferon‐based therapy in acute or chronic HCV were compared to those of participants with spontaneous clearance of infection, using Enzyme‐linked Immunospot (ELISPOT). PBMCs were available for 55 patients comprising 4 groups: spontaneous clearance (n = 17), acute interferon (n = 14), acute DAA (n = 13) and chronic DAA (n = 11). After controlling for sex, the magnitude of post‐treatment HCV‐specific responses after acute DAA treatment was greater than after chronic DAA or acute IFN treatment and similar to those found in spontaneous clearers. However, spontaneous clearers responded to more HCV peptide pools indicating greater breadth of response. In conclusion, early treatment with DAAs may prevent or reverse some degree of immune exhaustion and result in stronger HCV‐specific responses post‐treatment. However, individuals with spontaneous clearance had broader HCV‐specific responses. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

190. People engaged in opioid agonist treatment as a counterpublic during the COVID‐19 pandemic in Australia: A qualitative study.

Author

Conway, Anna, Treloar, Carla, Crawford, Sione, Grebely, Jason, and Marshall, Alison D.

Subjects
COVID-19 pandemic, NORMATIVITY (Ethics), OPIOIDS, QUALITATIVE research, WELL-being
Abstract

Introduction: People receiving opioid agonist treatment (OAT) are at higher risk of comorbidities, poverty and discrimination, which Big Events like the COVID‐19 pandemic may exacerbate. The behaviours of people receiving OAT do not always align with normative behaviours as conceived by ruling institutions and laws, and so the group becomes a counterpublic, not imagined in mainstream public discourse. The aim of this study was to understand how people receiving OAT, as a counterpublic, implemented practises of care to mitigate negative health outcomes during COVID‐19. Methods: Participants were recruited via eight peer‐led organisations across Australia. In‐depth, semi‐structured interviews were completed between August and December 2020 with 40 people receiving OAT. The analysis centres practises of care, allowing interactions that influence the health of participants, to be understood in their unique contexts. Results: Aspects of the COVID‐19 state response were designed for an idealised public, demonstrated by the increased policing that accompanied enforcement of restrictions which was detrimental to the wellbeing of people receiving OAT. Counterpublic health strategies employed by people receiving OAT were disrupted, but participants were often able to adapt to the changing context. Discussion and Conclusion: This study elucidates how practises of care among people receiving OAT are enacted and disrupted during a Big Event, with implications beyond the COVID‐19 pandemic for future Big Events. The study findings evidence the need for policies that mitigate the impact of Big Events such as supporting re‐groupment within the counterpublic, legitimising counterpublic health strategies and stopping the criminalisation of people who use drugs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

192. Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection

Author

Matthews, Gail V., primary, Bhagani, Sanjay, additional, Van der Valk, Marc, additional, Rockstroh, Juergen, additional, Feld, Jordan J., additional, Rauch, Andri, additional, Thurnheer, Christine, additional, Bruneau, Julie, additional, Kim, Arthur, additional, Hellard, Margaret, additional, Shaw, David, additional, Gane, Ed, additional, Nelson, Mark, additional, Ingiliz, Patrick, additional, Applegate, Tanya L., additional, Grebely, Jason, additional, Marks, Phillipa, additional, Martinello, Marianne, additional, Petoumenos, Kathy, additional, Dore, Gregory J., additional, van der Valk, Marc, additional, Dore, Greg, additional, Marks, Pip, additional, Matthews, Gail, additional, Applegate, Tanya, additional, Feld, Jordan, additional, Rockstroh, Jürgen, additional, Amjad, Sophia, additional, Tu, Elise, additional, Tamaddoni, Mahshid, additional, Thurnheer, Maria Christine, additional, Gilleece, Yvonne, additional, Fraser, Chris, additional, Moriggia, Alberto, additional, Lutz, Thomas, additional, Moon, Juhi, additional, Read, Phillip, additional, Kim, Arthur Y., additional, Ustianowski, Andrew, additional, Cordes, Christiane, additional, Sasadeusz, Joe, additional, Hull, Mark, additional, and Braun, Dominique, additional

Published
2021
Full Text
View/download PDF

193. Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs

Author

Grebely, Jason, primary, Collins, Alexandra B., additional, Artenie, Andreea Adelina, additional, Sutherland, Rachel, additional, Meyer, Jaimie P., additional, Barocas, Joshua A., additional, Falade-Nwulia, Oluwaseun, additional, Cepeda, Javier A., additional, Cunningham, Evan B., additional, Hajarizadeh, Behzad, additional, Lafferty, Lise, additional, Lazarus, Jeffrey V., additional, Bonn, Matthew, additional, Marshall, Alison D., additional, and Treloar, Carla, additional

Published
2021
Full Text
View/download PDF

196. Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence

Author

Santo, Thomas, primary, Clark, Brodie, additional, Hickman, Matt, additional, Grebely, Jason, additional, Campbell, Gabrielle, additional, Sordo, Luis, additional, Chen, Aileen, additional, Tran, Lucy Thi, additional, Bharat, Chrianna, additional, Padmanathan, Prianka, additional, Cousins, Grainne, additional, Dupouy, Julie, additional, Kelty, Erin, additional, Muga, Roberto, additional, Nosyk, Bohdan, additional, Min, Jeong, additional, Pavarin, Raimondo, additional, Farrell, Michael, additional, and Degenhardt, Louisa, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results